Minerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates
November 05, 2018 07:30 ET
|
Minerva Neurosciences, Inc
Data readouts from five ongoing late-stage trials expected in 2019 WALTHAM, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical...
Minerva Neurosciences to Report Third Quarter 2018 Financial Results and Business Updates on November 5, 2018
October 29, 2018 08:30 ET
|
Minerva Neurosciences, Inc
Management to host conference call WALTHAM, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the...
Minerva Neurosciences Announces Findings Showing Effect of Roluperidone on Brain-Derived Neurotrophic Factor (BDNF)
August 22, 2018 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Aug. 22, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Reports Second Quarter 2018 Financial Results and Business Updates
August 02, 2018 07:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Report Second Quarter 2018 Financial Results and Business Updates on August 2, 2018
July 26, 2018 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., July 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Names Devin Smith Senior Vice President, General Counsel
July 25, 2018 08:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors
July 17, 2018 16:05 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Present at Jefferies 2018 Global Healthcare Conference on June 6, 2018
May 30, 2018 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia
May 17, 2018 08:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates
May 03, 2018 07:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...